Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

FDARegulator guidanceAnalytical method validationMedicinesHigh confidenceLast verified October 4, 2026

FDA analytical procedures guidance

Analytical Procedures and Methods Validation for Drugs and Biologics

Current edition

July 2015

About this standard

Describes what analytical procedure and method validation information to submit in NDAs, ANDAs and BLAs, including validation characteristics, compendial procedures, reference standards and method transfer.

Recognition by market

Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts

No market listing is published yet.

Testing requirements that cite it

Open the market page and its pathway pages for the full requirement, protocol and report content

United States

Related standards: Q2(R2), USP <1224>, USP <1225>, USP <1226>, USP <621>, Q14, M10, ASEAN analytical validation guideline, RDC 166/2017, Taiwan analytical validation manual. See all standards.

Not legal or regulatory advice. Check the current official rules before you act. Parts of the approvals data are official open data reused under open licences. Data sources.

LinkedInLinkedInXXYouTubeYouTube